Literature DB >> 21975409

In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer.

Omar Alonso1, Juan P Gambini, Graciela Lago, Javier Gaudiano, Adriana Quagliata, Henry Engler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21975409     DOI： 10.1097/RLU.0b013e31822920c9

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


× No keyword cloud information.
  5 in total

1.  Positron emission tomographic imaging of copper 64- and gallium 68-labeled chelator conjugates of the somatostatin agonist tyr3-octreotate.

Authors:  Jessie R Nedrow; Alexander G White; Jalpa Modi; Kim Nguyen; Albert J Chang; Carolyn J Anderson
Journal:  Mol Imaging       Date:  2014       Impact factor: 4.488

2.  [Neuroendocrine prostate cancer].

Authors:  S Tritschler; R Erdelkamp; C Stief; M Hentrich
Journal:  Pathologe       Date:  2018-07       Impact factor: 1.011

3.  [Neuroendocrine prostate cancer].

Authors:  S Tritschler; R Erdelkamp; C Stief; M Hentrich
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

Review 4.  A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer.

Authors:  Ephraim E Parent; Adam M Kase
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

5.  PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors.

Authors:  Martina Sollini; Paola Anna Erba; Alessandro Fraternali; Massimiliano Casali; Maria Liberata Di Paolo; Armando Froio; Andrea Frasoldati; Annibale Versari
Journal:  ScientificWorldJournal       Date:  2014-02-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.